deamino-arginine-vasopressin and Infant--Premature--Diseases

Central diabetes insipidus (CDI) may occur in the setting of intracranial abnormalities that affect the hypothalamus-pituitary system. It occurs rarely in neonates, especially in the premature population, and represents a challenging disease process to treat pharmacologically. Little is known regarding the treatment options in premature infants, including dose and route of administration of intravenous desmopressin (DDAVP). We present a case of a late premature male infant with gastroschisis and septo-optic dysplasia who developed transient CDI. He was treated with intravenous DDAVP but required frequent laboratory monitoring and a multidisciplinary approach, and ultimately his CDI resolved. Although there are minimal guidelines regarding the appropriate formulation and dosage of DDAVP for management of CDI in infants, we initiated the lowest dose available and titrated the medication based on close monitoring of urine output and serum sodium levels in order to successfully treat his transient CDI.

Topics: Deamino Arginine Vasopressin; Diabetes Insipidus, Neurogenic; Humans; Infant, Premature; Infant, Premature, Diseases; Male; Septo-Optic Dysplasia

As neonatal central diabetes insipidus is rare in preterm neonates with intraventricular hemorrhage (IVH), very little is known about dosing and the route of administration of desmopressin treatment.. We present a preterm neonate born at 29 weeks' gestation. Within 24 h, she developed bilateral IVH with subsequent post-hemorrhagic hydrocephalus. On the 3rd postnatal day, she developed diabetes insipidus for which she was intranasally administered 0.2 mg desmopressin. This resulted in oliguria with several hours of anuria and a 25-point drop in sodium levels within 15 h.. The determination of the desmopressin dose in a preterm neonate is a challenge and there is no consistent literature about the dosing or the route of administration. We suggest starting with a low dose of intranasal desmopressin (0.05-0.1 μg) and titrate in accordance with clinical and laboratory parameters.

Topics: Administration, Intranasal; Cerebral Hemorrhage; Deamino Arginine Vasopressin; Diabetes Insipidus; Female; Humans; Hydrocephalus; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases

Topics: Antidiuretic Agents; Cerebral Hemorrhage; Deamino Arginine Vasopressin; Diabetes Insipidus; Humans; Hypernatremia; Infant, Newborn; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Male

We report a case of a premature very low birth weight infant who presented shortly after birth with idiopathic central diabetes insipidus that persisted beyond the neonatal period and has been successfully managed with intranasal 1-desamino-8-D-arginine vasopressin. Although this condition is rare in neonates, early recognition, evaluation, and therapy may prevent more severe morbidity. Long-term successful management resulting in normal growth and development during infancy can be achieved with intranasal 1-desamino-8-D-arginine vasopressin therapy.

Topics: Administration, Intranasal; Deamino Arginine Vasopressin; Diabetes Insipidus; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Male; Renal Agents

We report a case of neurogenic diabetes insipidus in a premature infant. It was treated with desmopressin, which appears to be the drug of choice for the treatment of this disease in early infancy.

Topics: Adult; Arginine Vasopressin; Deamino Arginine Vasopressin; Diabetes Insipidus; Diseases in Twins; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Male